{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:54:09Z","timestamp":1787025249613,"version":"build-2736575974"},"reference-count":34,"publisher":"Oceanside Publications Inc.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    The ACAAI\/\/AAAAI Joint Task Force on Practice Parameters periodically develops updated guidance based on all available evidence.\n                    <jats:bold>Methods:<\/jats:bold>\n                    This review summarizes advances in diagnosis and management of insect sting allergy from published practice\n parameters, and developments under review for the 2026 update.\n                    <jats:bold>Results:<\/jats:bold>\n                    Changes in the species and distribution of stinging insects in the US may be due to migration and invasion. Overall prevalence has not changed, but fatalities from insect sting allergy increased 50%\n in 30 years. Diagnostic evaluation includes both skin and serum immunoglobulinE testing although positive predictive value is dependent on the history. Evaluation may include venom component testing. Mastocytosis and hereditary alpha tryptasemia must be considered in many cases; testing for\n baseline serum tryptase is now routine. Testing for c-KIT gene mutation in peripheral blood and tryptase genotype are important supplemental tests. The risk of beta blockers and angiotensin converting enzyme inhibitors is relatively low in most cases, and they are not contraindicated during\n venom immunotherapy (VIT). VIT is indicated in high-risk patients (30\u201070% risk of anaphylaxis), but is not required in those with cutaneous reactions (3\u201010% risk of anaphylaxis). VIT can be safely initiated with rush regimens. Recurrent systemic reactions are rare, and may require\n omalizumab treatment (off-label). VIT can be discontinued after 5 years in most patients, but extended or indefinite VIT (often at 12-week intervals) is recommended in patients with known high-risk factors or where stopping would cause markedly impaired quality of life.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Continued research has refined our clinical approach to patients with concerns about stinging insect hypersensitivity.\n                  <\/jats:p>","DOI":"10.2500\/aap.2025.46.250060","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T04:36:17Z","timestamp":1758083777000},"page":"382-387","source":"Crossref","is-referenced-by-count":5,"title":["Update in stinging insect hypersensitivity"],"prefix":"10.2500","volume":"46","author":[{"given":"David B.K.","family":"Golden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.anai.2016.10.031","article-title":"Stinging insect hypersensitivity: a practice parameter update 2016","volume":"118","author":"Golden","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B2","first-page":"1","article-title":"Updates and recent advances on venom immunotherapy","author":"Floyd","year":"2023","journal-title":"Curr Treat Options Allergy"},{"key":"B3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/cea.14063","article-title":"The Asian wasp Vespa velutina nigrithorax: entomological and allergological characteristics","volume":"52","author":"Vidal","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"B4"},{"key":"B5"},{"key":"B6","doi-asserted-by":"crossref","first-page":"756","DOI":"10.15585\/mmwr.mm7227a6","article-title":"QuickStats: number of deaths from hornet, wasp, and bee stings* among males and females - National Vital Statistics System, United States, 2011\u20132021","volume":"72","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0091-6749(73)90044-4","article-title":"Studies of 400 Hymenoptera sting deaths in the United States","volume":"52","author":"Barnard","year":"1973","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.mcna.2005.08.006","article-title":"Insect sting allergy","volume":"90","author":"Graft","year":"2006","journal-title":"Med Clin North Am"},{"key":"B9","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaci.2005.12.1313","article-title":"Clinical and entomological factors influence the outcome of sting challenge studies","volume":"117","author":"Golden","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0091-6749(97)70222-7","article-title":"Timing of venom skin tests and IgE determinations after insect sting anaphylaxis","volume":"100","author":"Goldberg","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"e13854","DOI":"10.1111\/pai.13854","article-title":"EAACI Molecular Allergology User's Guide 2.0","volume":"34","author":"Dramburg","year":"2023","journal-title":"Pediatr Allergy Immunol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0091-6749(05)80012-0","article-title":"Natural history of insect sting allergy: relationship of severity of symptoms of initial sting anaphylaxis to re-sting reactions","volume":"90","author":"Reisman","year":"1992","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2500\/aap.2024.45.240035","article-title":"Efficacy and safety of Hymenoptera venom immunotherapy","volume":"45","author":"Kayikci","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"B14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0091-6749(94)90351-4","article-title":"Lack of reproducibility of a single negative sting challenge response in the assessment of anaphylactic risk in patients with suspected yellow jacket hypersensitivity","volume":"93","author":"Franken","year":"1994","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.anai.2023.09.015","article-title":"Anaphylaxis: a 2023 practice parameter update","volume":"132","author":"Golden","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B16","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaci.2009.08.027","article-title":"Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase\u2014a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity","volume":"124","author":"Rueff","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","article-title":"Heritable risk for severe anaphylaxis associated with increased alpha-tryptase-encoding germline copy number at TPSAB1","volume":"147","author":"Lyons","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jaci.2021.02.043","article-title":"Routine KIT p.D816V screening identifies clonal mast cell disease in patients with Hymenoptera allergy regularly missed using baseline tryptase levels alone","volume":"148","author":"Selb","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2014.11.035","article-title":"Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels","volume":"136","author":"Zanotti","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jaip.2017.02.008","article-title":"Risk factor analysis of anaphylactic reactions in patients with systemic mastocytosis","volume":"5","author":"G\u00fclen","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B22","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaci.2023.08.015","article-title":"Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes","volume":"153","author":"Polivka","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000329856","article-title":"Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms","volume":"157","author":"Alvarez-Twose","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/cea.14264","article-title":"Clonal mast cell disorders and hereditary \u03b1-tryptasemia as risk factors for anaphylaxis","volume":"53","author":"Kacar","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"B25","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jaip.2018.10.042","article-title":"Relationship between anaphylaxis and use of beta-blockers and angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis of observational studies","volume":"7","author":"Tejedor-Alonso","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B26","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1111\/all.14785","article-title":"\u03b2-blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy","volume":"76","author":"Sturm","year":"2021","journal-title":"Allergy"},{"key":"B27","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJM199012063232305","article-title":"The value of immunotherapy with venom in children with allergy to insect stings","volume":"323","author":"Valentine","year":"1990","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jaci.2009.03.017","article-title":"Venom immunotherapy reduces large local reactions to insect stings","volume":"123","author":"Golden","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2012.02.022","article-title":"Ultrarush versus semirush initiation of insect venom immunotherapy: a randomized controlled trial","volume":"130","author":"Brown","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B30","article-title":"Instructions and dose schedule for allergenic extracts Hymenoptera venom products","year":"2022"},{"key":"B31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1081-1206(10)61689-4","article-title":"Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy","volume":"91","author":"Goldberg","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B32","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0091-6749(96)70302-0","article-title":"Discontinuing venom immunotherapy: outcome after five years","volume":"97","author":"Golden","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"B33","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0091-6749(98)70167-8","article-title":"Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients","volume":"101","author":"Lerch","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0091-6749(00)90092-7","article-title":"Survey of patients after discontinuing venom immunotherapy","volume":"105","author":"Golden","year":"2000","journal-title":"J Allergy Clin Immunol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000005\/art00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T04:39:38Z","timestamp":1759552778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.250060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9,1]]}},"alternative-id":["1088-5412(20250901)46:5L.382;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.250060","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}